This is for new lookers and longs there is a phone
Post# of 6857
(Total Views: 558)
Posted On: 02/20/2022 3:34:51 AM
This is for new lookers and longs there is a phone number and email at the bottom of the releases for Pat Kelly, he is a very nice guy and I'm certain that he will be glad to talk with people on things he is able to do so about.
Read these 2 releases real good this should help new lookers these are from the people in the middle of it all.
Press Release:
February 03, 2022
University of Maryland and bioRemedies MD partner in CBD discovery
BALTIMORE, MARYLAND, UNITED STATES, February 3, 2022 /EINPresswire.com/ — Today, bioRemedies MD announced the launch of a new product line which is targeted to boost immunity and reduce inflammation. The line is supported by a report on the scientific benefits of combining herbal and cannabinoid (CBD) therapies issued by the Maryland University School of Integrated Health’s (MUIH) Herbal Product Design program.
“The Maryland University School of Integrated Health’s work strengthens the evidential narrative for the benefits of adjunct therapies derived from phytocannabinoids in combination with herbal remedies,” said Patrick Kelly, Managing Partner and founding member of bioRemedies MD. “Their effort to provide scientific validation and product placement support to companies, such as bioRemedies, in the herbal and cannabis marketplace is incredibly valuable.”
The study was completed by graduate students under the direction of Dr. Bhodi Tims, Director of the Herbal Product Design and Cannabis Science programs at MUIH, and with the support of faculty. As part of the final coursework in the Master’s in Herbal Product Design program, students work with companies facing real world challenges to provide peer reviewed evidence in support of particular therapies and effective decision-making matrixes that help the company identify best-fit solutions for their current development point.
“bioRemedies MD‘s work is helping to elevate the use of cannabinoids as medical therapeutic treatments,” said Dr.Bhodi Tims. “By partnering with companies like bioRemedies, our program is able to advance the understanding of the benefits of CBD and support the development of products and the market.”
In a pre-clinical study surrounding cannabinoids (CBD), a team led by University of Maryland School of Medicine’s Dr Ciaran Skerry, Phd has conducted pre-clinical research on mice utilizing a proprietary, custom blended CBD isolate from bioRemedies MD to understand the cannabinoid interactions surrounding whooping cough.
Preliminary findings are promising, noting a significant reduction in two key inflammatory cytokines, Tumor Necrosis Factor Alpha (TNF) and Interferon gamma (IFN-g). The ability of bioRemedies MD proprietary CBD has demonstrated that the TNF and IFN-g levels may assist with other inflammatory disorders.
bioRemedies MD is committed to developing adjunct therapies to reduce anxiety, boost the immune system, and reduce inflammation. Each of the company’s pharmaceutical grade and tested products are manufactured to ensure their quality, efficacy, and safety. bioRemedies MD’s enhanced drug delivery technology allows for a fast uptake with maximum absorption that deliver the required dosage for effective results.
About bioRemedies MD
Located in the University of Maryland BioPark in downtown Baltimore, bioRemedies MD entered the adjunct therapy market in 2013. Their therapies continue to lead to cutting-edge treatments for real world diseases and conditions. Recently, bioRemedies MD and Dr. David Dalton, CEO of UNIVEC Conglomerate Inc., established a a breakthrough partnership to offer adjunct, safe therapies for pain, anxiety and sleep disorders in the behavioral health setting in Maryland. For more information visit https://bioremediesmd.com/.
Be Well. Stay Kind.
Patrick Kelly
bioremedies
+ +1 4103405360
pat@bioremmd.com
Visit us on social media:
LinkedIn
Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
UNIVEC, Inc. and bioRemedies MD Align to Introduce products offering safe alternative to
pain, anxiety and sleep disorders
Baltimore, MD (October 28, 2021) – Dr. David Dalton, CEO of UNIVEC, Inc. (OTC Markets
UNVC)
and Patrick Kelly, President of bioRemedies MD, LLC announced a breakthrough partnership to
offer safe adjunct therapies for pain, anxiety and sleep disorders in the behavioral health
setting.
Through a variety of proprietary formulated cannabinoid-based products developed by
bioRemedies MD, Univec, Inc. is prepared to begin using these products in clinical behavioral
health settings for out-patient treatment. bioRemedies MD specializes in Cannabinoid
complementary and integrative products that have been in research and development at the
University of Maryland Baltimore BioPark since 2016 after industrial hemp research was
legitimized.
bioRemedies MD develops scientifically formulated cannabinoid products using FDA and
Pharmaceutical processes, technology, and standards to ensure high quality, reproducible, and
targeted formulations unlike anything in the market today. Their proprietary nanotechnology
delivers cannabinoids efficiently and effectively, which is required for academic research and
healthcare target markets and allows our commercial products to compete on quality and cost.
Univec, Inc. (OTC Markets UNVC) is an organization with a mission to change the way
healthcare is delivered in America. Having recently announced the acquisition of several
community based out-patient mental health centers to treat behavioral health. bioRemedies
MD compliments Univec, Inc. (UNVC) principles--treating the patient as whole and applying
“Total Wraparound” for patient, family and caregiver support.
Patrick Kelly, President of bioRemedies MD, LLC, remarked, “the time is now to bring these
products to the community weary from substance use disorders and barriers to mental health
treatment. This partnership with Univec, Inc. meets people where they are to help those
suffering from pain, opioid misuse, anxiety and sleep disorders.
Univec, Inc. will make private label and bioRemedies MD products available through several
distribution channels, including the recently acquired mental health centers. For additional
information about access to treatment, contact
For more information call 410-340-5360 or email pat@bioremmd.com
Read these 2 releases real good this should help new lookers these are from the people in the middle of it all.
Press Release:
February 03, 2022
University of Maryland and bioRemedies MD partner in CBD discovery
BALTIMORE, MARYLAND, UNITED STATES, February 3, 2022 /EINPresswire.com/ — Today, bioRemedies MD announced the launch of a new product line which is targeted to boost immunity and reduce inflammation. The line is supported by a report on the scientific benefits of combining herbal and cannabinoid (CBD) therapies issued by the Maryland University School of Integrated Health’s (MUIH) Herbal Product Design program.
“The Maryland University School of Integrated Health’s work strengthens the evidential narrative for the benefits of adjunct therapies derived from phytocannabinoids in combination with herbal remedies,” said Patrick Kelly, Managing Partner and founding member of bioRemedies MD. “Their effort to provide scientific validation and product placement support to companies, such as bioRemedies, in the herbal and cannabis marketplace is incredibly valuable.”
The study was completed by graduate students under the direction of Dr. Bhodi Tims, Director of the Herbal Product Design and Cannabis Science programs at MUIH, and with the support of faculty. As part of the final coursework in the Master’s in Herbal Product Design program, students work with companies facing real world challenges to provide peer reviewed evidence in support of particular therapies and effective decision-making matrixes that help the company identify best-fit solutions for their current development point.
“bioRemedies MD‘s work is helping to elevate the use of cannabinoids as medical therapeutic treatments,” said Dr.Bhodi Tims. “By partnering with companies like bioRemedies, our program is able to advance the understanding of the benefits of CBD and support the development of products and the market.”
In a pre-clinical study surrounding cannabinoids (CBD), a team led by University of Maryland School of Medicine’s Dr Ciaran Skerry, Phd has conducted pre-clinical research on mice utilizing a proprietary, custom blended CBD isolate from bioRemedies MD to understand the cannabinoid interactions surrounding whooping cough.
Preliminary findings are promising, noting a significant reduction in two key inflammatory cytokines, Tumor Necrosis Factor Alpha (TNF) and Interferon gamma (IFN-g). The ability of bioRemedies MD proprietary CBD has demonstrated that the TNF and IFN-g levels may assist with other inflammatory disorders.
bioRemedies MD is committed to developing adjunct therapies to reduce anxiety, boost the immune system, and reduce inflammation. Each of the company’s pharmaceutical grade and tested products are manufactured to ensure their quality, efficacy, and safety. bioRemedies MD’s enhanced drug delivery technology allows for a fast uptake with maximum absorption that deliver the required dosage for effective results.
About bioRemedies MD
Located in the University of Maryland BioPark in downtown Baltimore, bioRemedies MD entered the adjunct therapy market in 2013. Their therapies continue to lead to cutting-edge treatments for real world diseases and conditions. Recently, bioRemedies MD and Dr. David Dalton, CEO of UNIVEC Conglomerate Inc., established a a breakthrough partnership to offer adjunct, safe therapies for pain, anxiety and sleep disorders in the behavioral health setting in Maryland. For more information visit https://bioremediesmd.com/.
Be Well. Stay Kind.
Patrick Kelly
bioremedies
+ +1 4103405360
pat@bioremmd.com
Visit us on social media:
Leaders in Health Industry Join Forces to Address Mental Health and Substance Use
Disorder
UNIVEC, Inc. and bioRemedies MD Align to Introduce products offering safe alternative to
pain, anxiety and sleep disorders
Baltimore, MD (October 28, 2021) – Dr. David Dalton, CEO of UNIVEC, Inc. (OTC Markets
UNVC) and Patrick Kelly, President of bioRemedies MD, LLC announced a breakthrough partnership to
offer safe adjunct therapies for pain, anxiety and sleep disorders in the behavioral health
setting.
Through a variety of proprietary formulated cannabinoid-based products developed by
bioRemedies MD, Univec, Inc. is prepared to begin using these products in clinical behavioral
health settings for out-patient treatment. bioRemedies MD specializes in Cannabinoid
complementary and integrative products that have been in research and development at the
University of Maryland Baltimore BioPark since 2016 after industrial hemp research was
legitimized.
bioRemedies MD develops scientifically formulated cannabinoid products using FDA and
Pharmaceutical processes, technology, and standards to ensure high quality, reproducible, and
targeted formulations unlike anything in the market today. Their proprietary nanotechnology
delivers cannabinoids efficiently and effectively, which is required for academic research and
healthcare target markets and allows our commercial products to compete on quality and cost.
Univec, Inc. (OTC Markets
UNVC) is an organization with a mission to change the way healthcare is delivered in America. Having recently announced the acquisition of several
community based out-patient mental health centers to treat behavioral health. bioRemedies
MD compliments Univec, Inc. (UNVC) principles--treating the patient as whole and applying
“Total Wraparound” for patient, family and caregiver support.
Patrick Kelly, President of bioRemedies MD, LLC, remarked, “the time is now to bring these
products to the community weary from substance use disorders and barriers to mental health
treatment. This partnership with Univec, Inc. meets people where they are to help those
suffering from pain, opioid misuse, anxiety and sleep disorders.
Univec, Inc. will make private label and bioRemedies MD products available through several
distribution channels, including the recently acquired mental health centers. For additional
information about access to treatment, contact
For more information call 410-340-5360 or email pat@bioremmd.com
(8)
(0)Scroll down for more posts ▼